The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Age was associated with overall survival and the time to Richter transformation in adolescent and young adult patients with chronic lymphocytic leukemia, according to findings from a single-institutional, retrospective study.

The addition of neoadjuvant ipilimumab to nivolumab resulted in higher rates of major pathologic response and pathologic complete response, while enhancing tumor immune cell infiltrates in patients with resectable non–small cell lung cancer, according to data from the phase 2 NEOSTAR trial.

Jason Niu, MD, PhD, discusses considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.

UCARTCS1A demonstrated early antitumor activity in heavily pretreated patients with relapsed/refractory multiple myeloma in whom previous CAR T-cell therapy and/or transplant had failed, according to preliminary data from the phase 1 MELANI-01 trial.

Helen J. Ross, MD, discusses the utility of first- and second-generation EGFR inhibitors in EGFR-mutant non–small cell lung cancer.

Kanwal Raghav, MBBS, MD, discusses adjusting dosing with regorafenib in patients with colorectal cancer.

Srdan Verstovsek, MD, PhD, discusses real-world survival data with ruxolitinib in myelofibrosis.

Michael A. Davies, MD, PhD, discusses the potential utility of ERK inhibitors in melanoma.

Richard Gorlick, MD, discusses the challenges of identifying immunotherapeutic targets in osteosarcomas.

Srdan Verstovsek, MD, PhD, discusses the efficacy of ruxolitinib in combination with CPI-0610 in myelofibrosis.

Michael A. Davies, MD, PhD, discusses the management of patients with melanoma during the COVID-19 pandemic.

Richard Gorlick, MD, discusses the potential of antibody-drug conjugates in patients with osteosarcoma.

Richard Gorlick, MD, highlights methods for identifying immunotherapeutic targets in osteosarcomas.

Srdan Verstovsek, MD, PhD, discusses the potential clinical utility of luspatercept-aamt in myelofibrosis.

Dr. Fowler discusses the data that served as the basis for the accelerated approval of umbralisib in marginal zone lymphoma and follicular lymphoma, the implications of the regulatory decision on clinical practice, and potential next steps for the PI3Kδ and CK1ε inhibitor.

Srdan Verstovsek, MD, PhD, discusses the role of prognostication in myelofibrosis.

Nageshwara Arvind Dasari, MD, discusses the eligibility criteria for the phase 3 FRESCO-2 trial, which examined the use of fruquintinib in patients with metastatic colorectal cancer.

Michael A. Davies, MD, PhD, discusses the potential role of novel BRAF inhibitors in treating patients with melanoma and brain metastases.

Immunotherapy is now incorporated into National Comprehensive Cancer Network guidelines as maintenance therapy and in a sequencing strategy for the treatment of patients with metastatic urothelial carcinoma and in the setting of superficial UC-carcinoma in situ with prior intravesical therapy.

John V. Heymach, MD, PhD, discusses the incidence of EGFR exon 20 insertions in lung cancer, diagnostic challenges of identifying EGFR exon 20 insertions, and data from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with mobocertinib and amivantamab in this patient subset.

Srdan Verstovsek, MD, PhD, shares recommendation updates for myelofibrosis treatment and emerging options under exploration to effectively manage disease-related symptoms.

Hun Ju Lee, MD, discusses a phase 1/2 study evaluating cirmtuzumab in combination with ibrutinib in patients with mantle cell lymphoma or chronic lymphocytic leukemia.

John V. Heymach, MD, PhD, discusses the efficacy of mobocertinib in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

Michael A. Davies, MD, PhD, discusses the utility of retreatment with combination BRAF/MEK inhibitors in BRAF-mutant melanoma.

Aung Naing, MD, FACP, discusses potential immune-related adverse effects in oncology.

John V. Heymach, MD, PhD, discusses the potential utility of afatinib in NRG1 fusion–positive non–small cell lung cancer.

ADP-A2M4CD8, a novel T-cell therapy, is being investigated in a range of tumor types that express MAGEA4, an antigen expressed in solid tumors that investigators say represents a promising target for cellular immunotherapy.

Hun Ju Lee, MD, discusses potential challenges with VLS-101 in mantle cell lymphoma and diffuse large B-cell lymphoma.

Nageshwara Arvind Dasari, MD, discusses the rationale to evaluate fruquintinib in the ongoing, phase 3 FRESCO-2 trial in patients with metastatic colorectal cancer.

Srdan Verstovsek, MD, PhD, discusses the use of luspatercept to treat anemia associated with myelofibrosis.